Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on August 11, 2008
JNCI Journal of the National Cancer Institute 2008 100(16):1132-1133; doi:10.1093/jnci/djn300
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/16/1132    most recent
djn300v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vastag, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vastag, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

Preventing Prostate Cancer: New Analyses Put Finasteride Back on the Map

Brian Vastag

The first 10% of the full text of this article appears below.

In 2003, when investigators from the National Cancer Institute and the Southwest Oncology Group published initial results from the Prostate Cancer Prevention Trial (PCPT), an anomaly arose.

The study found that the drug finasteride reduced the relative risk of a prostate cancer diagnosis by about 25%. That is, 24.4% of men taking placebo were diagnosed with prostate cancer, whereas 18.4% of men taking finasteride got the diagnosis. Alone, that finding would have been a major advance in prostate cancer prevention.

But at the same time, the study data showed an increase in high-grade cancers in men taking finasteride. Those cancers are the most troubling because they tend to grow and spread quickly.

The results confounded study investigators and stymied the adoption of finasteride—which is approved by the U.S. Food and Drug Administration to treat benign prostate hyperplasia—for prostate cancer prevention.

Later, some prostate cancer experts suggested . . . [Full Text of this Article]

High-grade Tumors Explained

Clinically Significant Tumors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J EpidemiolHome page
J. Li, R. J. Coates, M. Gwinn, and M. J. Khoury
Steroid 5-{alpha}-Reductase Type 2 (SRD5a2) Gene Polymorphisms and Risk of Prostate Cancer: A HuGE Review
Am. J. Epidemiol., November 13, 2009; (2009) kwp318v1.
[Abstract] [Full Text] [PDF]